ANCA-ASSOCIATED VASCULITIS
Clinical trials for ANCA-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANCA-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hydroxychloroquine trial for rare vasculitis halted early
Disease control TerminatedThis study tested whether adding hydroxychloroquine to standard treatments could help control ANCA vasculitis, a group of autoimmune diseases that cause inflammation of blood vessels. The trial was open to adults with certain types of vasculitis who had mild disease activity. Par…
Matched conditions: ANCA-ASSOCIATED VASCULITIS
Phase: PHASE4 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated May 26, 2026 05:10 UTC
-
Promising vasculitis drug trial halted early
Disease control TerminatedThis study tested a new drug, obinutuzumab, against the standard drug rituximab for people with a rare autoimmune disease that inflames blood vessels (ANCA-associated vasculitis). The goal was to see if obinutuzumab could better stop disease activity and clear harmful antibodies.…
Matched conditions: ANCA-ASSOCIATED VASCULITIS
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Blood test may predict vasculitis relapse, study hints
Knowledge-focused TerminatedThis study looked at whether measuring certain immune cells (CD5+ regulatory B cells) after initial treatment could help doctors decide who needs ongoing therapy for ANCA vasculitis, a rare blood vessel disease. The idea was that patients whose immune cells recovered well might s…
Matched conditions: ANCA-ASSOCIATED VASCULITIS
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated May 26, 2026 05:08 UTC